BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Tag: Malignant neoplasm › COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.

Dataset: COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.

Biomarkers that predict disease progression might assist the development of better therapeutic strategies for aggressive cancers, such as...

Registered by ArrayExpress Uploader
View Dataset

Biomarkers that predict disease progression might assist the development of better therapeutic strategies for aggressive cancers, such as ovarian cancer. Here, we investigated the role of collagen type XI alpha 1 (COL11A1) in cell invasiveness and tumor formation and the prognostic impact of COL11A1 expression in ovarian cancer. Microarray analysis suggested that COL11A1 is a disease progression-associated gene that is linked to ovarian cancer recurrence and poor survival. Whole tumor gene expression profiling was conducted on tissue samples from 60 ovarian cancer patients, and characteristics and clinico-pathological features of the patients are provided. We used several steps to analyze the expression profiles of the samples to identify the genes whose expression values correlate with survival, recurrence and advanced disease stage. First, using hazard ratios from univariate Cox regression analysis, the top 200 survival-related genes were evaluated for intersection with the top 200 recurrence-related genes, and 44 genes were obtained. Second, we examined the 44 genes that met the criteria of fold-change values between advanced stage and early stage samples of greater than 2 or less than 0.5. Ultimately, 17 genes were identified. A heat map of the 17 genes is depicted in the associated publication. Gene ontology and pathway enrichment analyses of the 17 genes were performed using Database for Annotation, Visualization and Integrated Discovery (DAVID). The major cellular component, biological process and molecular function of the 17 genes are associated with the extracellular region, intracellular signaling cascade, and protein binding and bridging, respectively. Two genes, COL11A1 and COL4A6, are involved in ECM-receptor interaction pathways. Notably, COL11A1 displayed the highest fold-change value in ovarian cancer disease progression; therefore, we selected COL11A1 for further experimental analysis.

Species:
human

Samples:
60

Source:
E-GEOD-44104

Updated:
Dec.12, 2014

Registered:
Jul.11, 2014


Factors: (via ArrayExpress)
Sample TISSUE SUBTYPE SURVIVAL/DEATH ADVANCED DISEASE STAGE RECURRENCE STATUS
GSM107903 serous survival stage III recurrence
GSM1079030 serous Death stage IV recurrence
GSM1079029 serous Death stage III recurrence
GSM1079028 serous survival stage III non-recurrence
GSM1079027 serous survival stage II non-recurrence
GSM1079026 serous survival stage IV non-recurrence
GSM1079027 serous survival stage II non-recurrence
GSM1079028 serous survival stage III non-recurrence
GSM107903 serous survival stage III recurrence
GSM107903 serous survival stage III recurrence
GSM1079028 serous survival stage III non-recurrence
GSM107903 serous survival stage III recurrence
GSM1079028 serous survival stage III non-recurrence
GSM1079028 serous survival stage III non-recurrence
GSM1079028 serous survival stage III non-recurrence
GSM1079028 serous survival stage III non-recurrence
GSM1079029 serous Death stage III recurrence
GSM1079028 serous survival stage III non-recurrence
GSM1079029 serous Death stage III recurrence
GSM107903 serous survival stage III recurrence
GSM1079029 serous Death stage III recurrence
GSM107903 serous survival stage III recurrence
GSM1079009 serous Death stage III non-recurrence
GSM1079029 serous Death stage III recurrence
GSM1079007 serous Death stage I recurrence
GSM1079006 serous survival stage I non-recurrence
GSM1079029 serous Death stage III recurrence
GSM107903 serous survival stage III recurrence
GSM1079003 mucinous Death stage II recurrence
GSM1079002 mucinous survival stage I non-recurrence
GSM107900 mucinous survival stage II non-recurrence
GSM1079002 mucinous survival stage I non-recurrence
GSM1079002 mucinous survival stage I non-recurrence
GSM1078998 mucinous survival stage III non-recurrence
GSM1079002 mucinous survival stage I non-recurrence
GSM1079002 mucinous survival stage I non-recurrence
GSM1078995 mucinous Death stage III non-recurrence
GSM1078994 endometrioid survival stage II non-recurrence
GSM1078993 endometrioid survival stage I non-recurrence
GSM1078992 endometrioid Death stage III recurrence
GSM107899 endometrioid survival stage IV non-recurrence
GSM1078993 endometrioid survival stage I non-recurrence
GSM1078989 endometrioid survival stage III non-recurrence
GSM1078994 endometrioid survival stage II non-recurrence
GSM1078993 endometrioid survival stage I non-recurrence
GSM1078993 endometrioid survival stage I non-recurrence
GSM1078985 endometrioid Death stage II non-recurrence
GSM1078984 endometrioid Death stage I non-recurrence
GSM1078983 clear cell Death stage IV non-recurrence
GSM1078982 clear cell survival stage IV recurrence
GSM107898 clear cell survival stage II recurrence
GSM1078980 clear cell survival stage I non-recurrence
GSM1078980 clear cell survival stage I non-recurrence
GSM1078978 clear cell survival stage III non-recurrence
GSM1078980 clear cell survival stage I non-recurrence
GSM1078980 clear cell survival stage I non-recurrence
GSM1078978 clear cell survival stage III non-recurrence
GSM1078980 clear cell survival stage I non-recurrence
GSM1078973 clear cell Death stage III recurrence
GSM1078978 clear cell survival stage III non-recurrence

Tags

  • cancer
  • cell
  • collagen
  • disease
  • ovarian cancer
  • protein

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2025 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use